Table 1.
Study characteristics
| Study (reference) | Country | Evidence | Inclusion period | Total a | Total (B)RPC + FFX | Definition resectability | Radiotherapy, No. (%) | Chemotherapy | Radiotherapy | Adjuvant therapy, No. (%) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regimen | Neoadj. cycles, median (range) | Type | CRT regimen | Dose, fractions | |||||||||
| FOLFIRINOX alone | |||||||||||||
| Barenboim22 | Israel | Retrospective | 2008–2017 | 100 | 23 | NCCN | 2 (8.7) | FOLFIRINOX | 8 (5–14) | – | – | – | 16 (70.0) |
| Dhir36 | USA | Retrospective | 2011–2017 | 193 | 73b | NCCN | 0 (0.0) | FOLFIRINOX | 3 (IQR 3–4) | – | – | – | 54 (73.9) |
| Okada23 | Japan | Prospective | 2014–2015 | 10 | 10 | NCCN | 0 (0.0) | mFOLFIRINOX e | 6 (4–8) | – | – | – | 8 (80.0) |
| Tinchon24 | Austria | Prospective | 2010–2012 | 12 | 10 | AHPBA/SSO/SSAT | 0 (0.0) | FOLFIRINOX | 4 (4–6) | – | – | – | 0 |
| De Marsh34 | USA | Prospective | 2013–2015 | 21 | 21c | NCCN | 0 (0.0) | mFOLFIRINOX | 4 (NR–4) | – | – | – | 15 (71.4) |
| Kim35 | USA | Retrospective | 2011–2015 | 26 | 18d | NCCN | 0 (0.0) | FOLFIRINOX | 9 (4–12) | – | – | – | 7 (38.9) |
| Medrano25 | France | Retrospective | 2011–2018 | 139 | 121 | NCCN | 0 (0.0) | FOLFIRINOX | 4 (4–16) | – | – | – | 76 (62.8) |
| Yoo26 | South Korea | Retrospective | 2013–2017 | 199 | 75 | NCCN | 0 (0.0) | (m)FOLFIRINOX | 7 (1–41) | – | – | – | NR |
| Total | 700 | 351 | 2 (0.6) | 5 (3–9) | 176 (58.2) | ||||||||
| FOLFIRINOX with radiotherapy | |||||||||||||
| Christians27 | USA | Retrospective | 2010–2012 | 18 | 18 | MCW | 18 (100.0) | FOLFIRINOX | 4 (3–8) | CRT | Gemcitabine/ capecitabine | 50.4 Gy, 28 | 1 (5.6) |
| Katz28 | USA | Prospective | 2013–2014 | 22 | 22 | ALLIANCE | 21 (95.5) | mFOLFIRINOX | 4 (NR) | CRT | Capecitabine | 50.4 Gy, 28 | 10 (45.5) |
| Murphy29 | USA | Prospective | 2012–2016 | 48 | 48 | NR | 44 (91.7) | FOLFIRINOX | 8 (NR) | CRT | Capecitabine/5-fluorouracil | 25.0 Gy, 5 /30.0 Gy, 10 /50.4 Gy, 28 g | 5 (10.4) |
| Shaib30 | USA | Prospective | NR | 13 | 13 | ALLIANCE | 12 (92.3) | mFOLFIRINOX | 4 (NR) | SBRT | – | 36 - 45 Gy, 3 | 0 |
| Tran31 | USA | Prospective | 2011–2017 | 25 | 25 | NCCN | 19 (76.0) | (m)FOLFIRINOX | 6 (NR) | CRT | Gemcitabine | 50.0 Gy, 25 | 0 |
| Bolton32 | USA | Retrospective | 2008–2015 | 195 | 31 | AHPBA/SSO/SSAT | 28 (90.3)f | FOLFIRINOX | 4 (3–5) | CRT | 5-Fluorouracil | NR | NR |
| Mahaseth33 | USA | Retrospective | 2010–2012 | 60 | 4 | NR | 4 (100.0) | mFOLFIRINOX | NR (2–6) | CRT | Gemcitabine/capecitabine | NR | NR |
| Total | 381 | 161 | 146 (90.7) | 4 (4–8) | 16 (6.0) | ||||||||
AHPBA/SSO/SSAT Americas Hepato-Pancreato-Biliary Association/Society of Surgical Oncology/Society for Surgery of the Alimentary Tract, (B)RPC resectable or borderline resectable pancreatic cancer, CRT chemoradiotherapy, FFX FOLFIRINOX, MCW Medical College of Wisconsin, MDACC MD Anderson Cancer Center, NCCN National Comprehensive Cancer Network, No. number, NR not reported, Neoadj. neoadjuvant, SBRT stereotactic body radiation therapy
aTotal patients included in study, bIncluding upfront resectable pancreatic cancer (n = 15), cAll upfront resectable pancreatic cancer, dIncluding upfront resectable pancreatic cancer (n = 5), eModified FOLFIRINOX without bolus 5-fluorouracil and leucovorin, and with reduced dose of irinotecan, fEstimation based on percentage mentioned in manuscript, gDepending on evaluation by multidisciplinary team; short-course chemotherapy with protons or photons for clearly resectable disease, long-course chemoradiotherapy using intensity modulated radiotherapy in case of persistent vascular involvement